SureTrader
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Boom. It really seems like the high TGs

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
iwfal Member Profile
Member Level 
Followed By 64
Posts 4,249
Boards Moderated 0
Alias Born 09/06/03
160x600 placeholder
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events "GlobeNewswire Inc." - 1/23/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/17/2018 5:59:57 PM
Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China "GlobeNewswire Inc." - 1/17/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/16/2018 6:01:23 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/9/2018 6:01:35 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/4/2018 4:57:25 PM
Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook "GlobeNewswire Inc." - 1/4/2018 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/2/2018 4:34:20 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 1/2/2018 4:33:51 PM
Amended Statement of Beneficial Ownership (3/a) "Edgar (US Regulatory)" - 12/22/2017 4:13:13 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 12/21/2017 4:04:15 PM
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018 "GlobeNewswire Inc." - 12/19/2017 6:00:00 AM
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco "GlobeNewswire Inc." - 12/18/2017 4:30:00 PM
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 12/4/2017 4:48:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/4/2017 9:04:12 AM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular ... "GlobeNewswire Inc." - 11/14/2017 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Pat... "GlobeNewswire Inc." - 11/13/2017 4:30:00 PM
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical ... "GlobeNewswire Inc." - 11/13/2017 6:00:00 AM
Amarin to Present at the Jefferies London Healthcare Conference "GlobeNewswire Inc." - 11/7/2017 6:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/1/2017 6:35:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/1/2017 6:31:37 AM
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 11/1/2017 5:30:00 AM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 "GlobeNewswire Inc." - 10/25/2017 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/6/2017 7:23:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:27 PM
iwfal Member Level  Friday, 10/06/17 12:02:47 AM
Re: tasgrewaf post# 115577
Post # of 121198 
Quote:
Boom. It really seems like the high TGs are the symptom of something else more important going wrong.



I agree that this is probably true - the APOC3 trials by IONS had surprising results on glucose control. Anyone who was paying attention was surprised that something that was expected to only directly influence lipids had a dramatic effect on glucose. (and I give the CEO a lot of credit for really focusing the Ph2s on this - so he'd know.)

And part of the reason I watch AMRN is because I am interested in this nexus - i.e. I will be interested in all the secondary endpoints for the Vascepa ph3.

That said, of course I think the trial has a LOT of risk. In a way very similar to ONTY - I think it likely it has some interesting benefit somewhere, but probably not enough on the primary endpoint (or has enough side effects to cause it not to be worthwhile.).


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist